Gene Network Sciences Using Supercomputing to Match Patients with a Drug That Works | Xconomy
Summary
It is using supercomputing technology to build databases that can match patients with the most suitable drugs or other treatments, company CEO Colin Hill says. Since the Cornell physicists Hill and Iya Khalil formed the startup in 2000, it’s been known mostly for performing computer-simulated drug research with its signature reverse engineering/forward simulation technology for such major companies as Biogen Idec (NASDAQ:BIIB), Johnson & Johnson (NYSE:JNJ), and Pfizer (NYSE:PFE). While Gene Network Sciences is continuing to work in drug research and development, Hill says, the healthcare market has been a major focus for the firm over the past year. These outfits, such as CVS Caremark (NYSE:CVS) and Medco Health Solutions (NYSE:MHS), handle prescription drug plans for more than 210 million Americans, the majority of the total U.S. population, according to the Pharmacy Care Management Association, an industry group based in Washington, DC. The PBMs, as they are often called, have already adopted e-prescribing to reduce errors and streamline how doctors order prescriptions for patients, and Hill says these companies have also implemented computer models.
Classifications
AskAI Classifications
LabelsLinked Companies
